Patients who require more than one glucose-lowering medicine may receive DPP-4 inhibitors as part of combination treatment. Their integration with other therapeutic classes provides physicians with additional options for individualized management. This role is contributing to continued clinical relevance. The Dipeptidyl Peptidase-4 Inhibitors Market is expected to reach US$ 14.19 billion by...